Harpoon Therapeutics snags $70 mln Series C

South San Francisco-based Harpoon Therapeutics Inc, a clinical-stage immunotherapy company, has raised $70 million in Series C financing. OrbiMed led the round with participation from other investors that included Cormorant, Ridgeback Capital Investments, Lilly Asia Ventures, NS Investment, MPM Capital, Oncology Impact Fund, Arix Bioscience, New Leaf Venture Partners and Taiho Ventures LLC.

ManagersNorth AmericaUSHealthcareBriefs